MX2024004766A - Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa. - Google Patents

Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa.

Info

Publication number
MX2024004766A
MX2024004766A MX2024004766A MX2024004766A MX2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A MX 2024004766 A MX2024004766 A MX 2024004766A
Authority
MX
Mexico
Prior art keywords
irritability
subjects
moderate
autism spectrum
treatment
Prior art date
Application number
MX2024004766A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Palumbo
Stephen V O''quinn
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2024004766A publication Critical patent/MX2024004766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024004766A 2021-10-22 2022-10-20 Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa. MX2024004766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163271015P 2021-10-22 2021-10-22
PCT/US2022/078449 WO2023070045A1 (en) 2021-10-22 2022-10-20 Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Publications (1)

Publication Number Publication Date
MX2024004766A true MX2024004766A (es) 2024-06-11

Family

ID=84358575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004766A MX2024004766A (es) 2021-10-22 2022-10-20 Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa.

Country Status (10)

Country Link
US (1) US20240342198A1 (enExample)
EP (1) EP4419091A1 (enExample)
JP (1) JP2024536581A (enExample)
KR (1) KR20240093852A (enExample)
CN (1) CN118284412A (enExample)
AU (1) AU2022373753A1 (enExample)
CA (1) CA3235677A1 (enExample)
IL (1) IL312328A (enExample)
MX (1) MX2024004766A (enExample)
WO (1) WO2023070045A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
CA3300266A1 (en) * 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
JP7856584B2 (ja) * 2020-05-26 2026-05-11 ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド カンナビジオールを用いた自閉症スペクトラム障害の処置
TWI902836B (zh) * 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
LT4243797T (lt) * 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui

Also Published As

Publication number Publication date
JP2024536581A (ja) 2024-10-04
CN118284412A (zh) 2024-07-02
CA3235677A1 (en) 2023-04-27
WO2023070045A1 (en) 2023-04-27
IL312328A (en) 2024-06-01
US20240342198A1 (en) 2024-10-17
AU2022373753A1 (en) 2024-05-09
KR20240093852A (ko) 2024-06-24
EP4419091A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
MX2021007076A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2022014912A (es) Tratamiento del trastorno del espectro autista con cannabidiol.
Wu et al. Autism spectrum disorder (ASD): disturbance of the melatonin system and its implications
Dear et al. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for social anxiety disorder and comorbid disorders: a randomized controlled trial
EP4414030A3 (en) Treatment of fragile x syndrome with cannabidiol
JOP20220061A1 (ar) علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
RU2013136378A (ru) Применение фитоканнабиноида каннабидиола(cbd) в комбинации со стандартным противоэпилептическим стедством(saed) для лечения эпилепсии
NZ716627A (en) Methods of treating behavioral symptoms of neurological and mental disorders
PH12020551427A1 (en) Epinephrine spray formulations
WO2023009834A3 (en) Methods of treating cancer
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
TN2019000019A1 (en) Treatment and prevention of sleep disorders
AU2018341331A1 (en) Improvement in cognitive function with fenfluramine
WO2009073544A3 (en) Methods for treating a disorder by regulating gprc6a
MX2024005002A (es) Métodos para tratar la endometriosis y otros trastornos ginecológicos no cancerosos con extracto de cáñamo.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
Parsa et al. The effect of pentoxifylline on chronic venous ulcers
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
JOP20220338A1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
UA101035C2 (ru) Смягчающая композиция на основе вазелина, глицерина и вазелинового масла
Whalen et al. Histamine and deep brain stimulation: the pharmacology of regularizing a brain
MY197721A (en) Composition and uses thereof
IL312328A (en) Treatment of irritability in patients on the autism spectrum with moderate to severe anxiety and/or social avoidance
MX2025013867A (es) Metodos para tratar el cancer en sujetos con exposicion previa a inhibidores de punto de control inmunitario
MX2023010115A (es) Tratamiento y/o reducción de la aparición de la migraña.